PYRUKYND is also approved for adults with PK deficiency in the U.S. and Europe, and a marketing application for PYRUKYND in thalassemia is currently under review by the European Commission. In the U.S ...
Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues ...
AstraZeneca received FDA approval for Calquence with venetoclax, creating the first all oral, fixed duration regimen for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. The ...
Also known as metastatic breast cancer (mBC), Stage IV means the disease has spread to other parts of the body, and approximately 1 in 3 people with breast cancer develop mBC.³ In Lynn’s case, her ...
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; ...
Addis is a city at a crossroads. A massive redevelopment project is reshaping Ethiopia’s capital into what Prime Minister ...
More than forty years after the crucial events in Canada’s tainted blood tragedy, a new documentary, Du sang sur les mains , will begin streaming on Illico+ on ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...
Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and ...
Discover how adult ADHD symptoms impact more than focus. Learn about the hidden cardiovascular, metabolic, and mental health risks.
A blood test measuring inflammation is now being used by cardiologists to predict heart problems, alongside traditional cholesterol tests.
Pfizer Inc. and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results